Reference is made to the extraordinary general meeting of the Company held on
17 September 2024, where it was resolved to consolidate the Company's shares.
Reference is further made to the warrants issued by the Company pursuant to a
resolution by the extraordinary general meeting of the Company held on 16 May
2024 (the "Warrants"). Pursuant to their terms, the Warrants shall be
consolidated in the same ratio as the shares. The following key information is
provided in connection with the consolidation (reverse split) of the shares
and Warrants:

Date on which the corporate action was made public: 17 September 2024.

Consolidation ratio for shares and Warrants: 13 old shares give 1 new share /
13 old Warrants give 1 new Warrant.

Last day including right: 30 September 2024.

Ex-date: 1 October 2024.

Record date: 2 October 2024.

Date of approval: 17 September 2024 (EGM date).

Other information: A new ISIN number will be issued for the shares. Further
information will be provided in a separate stock exchange announcement. The
Warrants will retain the same ISIN as used today.

This information is published in accordance with the requirements of the
Continuing Obligations.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")
on the sensor body for read-out of pressure variations. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-09-26 07:00 CEST.